12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Erbitux cetuximab regulatory update

Merck withdrew an MAA to extend the label for Erbitux cetuximab to include first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with high EGFR-expression in combination with platinum-based chemotherapy. The pharma said it withdrew the application based on feedback from EMA indicating that additional data...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >